Lilly takes GLP-1 crown from Novo

Lilly is once again at the top of the league for GLP-1 product sales, a position it has not held since 2021.

In 1Q22, blockbuster GLP-1R agonist Ozempic semaglutide surpassed Trulicity dulaglutide from Eli Lilly and Co. (NYSE:LLY), giving Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) the lead position in quarterly GLP-1 sales, a reign that lasted about three years. ...